AngioDynamics (ANGO) Competitors

AngioDynamics (NASDAQ:ANGO) and Thermo Fisher Scientific (NYSE:TMO) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings, media sentiment and analyst recommendations.

Does the media favor ANGO or TMO?

In the previous week, Thermo Fisher Scientific had 85 more articles in the media than AngioDynamics. MarketBeat recorded 89 mentions for Thermo Fisher Scientific and 4 mentions for AngioDynamics. Thermo Fisher Scientific's average media sentiment score of 1.20 beat AngioDynamics' score of 0.58 indicating that Thermo Fisher Scientific is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AngioDynamics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Thermo Fisher Scientific	60 Very Positive mention(s)	4 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Is ANGO or TMO more profitable?

Thermo Fisher Scientific has a net margin of 15.24% compared to AngioDynamics' net margin of -11.62%. Thermo Fisher Scientific's return on equity of 16.82% beat AngioDynamics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AngioDynamics	-11.62%	-3.20%	-2.09%
Thermo Fisher Scientific	15.24%	16.82%	8.38%

Do insiders and institutionals believe in ANGO or TMO?

89.4% of AngioDynamics shares are owned by institutional investors. Comparatively, 89.2% of Thermo Fisher Scientific shares are owned by institutional investors. 5.4% of AngioDynamics shares are owned by company insiders. Comparatively, 0.3% of Thermo Fisher Scientific shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Do analysts rate ANGO or TMO?

AngioDynamics presently has a consensus price target of $19.00, indicating a potential upside of 101.06%. Thermo Fisher Scientific has a consensus price target of $593.00, indicating a potential upside of 18.54%. Given AngioDynamics' stronger consensus rating and higher probable upside, equities research analysts plainly believe AngioDynamics is more favorable than Thermo Fisher Scientific.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AngioDynamics	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Thermo Fisher Scientific	0 Sell rating(s)	6 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.73

Which has preferable earnings and valuation, ANGO or TMO?

Thermo Fisher Scientific has higher revenue and earnings than AngioDynamics. AngioDynamics is trading at a lower price-to-earnings ratio than Thermo Fisher Scientific, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AngioDynamics	$292.50M	1.31	-$33.99M	-$0.83	-11.39
Thermo Fisher Scientific	$42.88B	4.41	$6.34B	$17.29	28.93

Which has more risk and volatility, ANGO or TMO?

AngioDynamics has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500. Comparatively, Thermo Fisher Scientific has a beta of 0.74, meaning that its stock price is 26% less volatile than the S&P 500.

Summary

Thermo Fisher Scientific beats AngioDynamics on 12 of the 16 factors compared between the two stocks.